PL172828B1 - Nowe zwiazki, pochodne hydrazonu PL PL PL PL PL - Google Patents
Nowe zwiazki, pochodne hydrazonu PL PL PL PL PLInfo
- Publication number
- PL172828B1 PL172828B1 PL93297514A PL29751493A PL172828B1 PL 172828 B1 PL172828 B1 PL 172828B1 PL 93297514 A PL93297514 A PL 93297514A PL 29751493 A PL29751493 A PL 29751493A PL 172828 B1 PL172828 B1 PL 172828B1
- Authority
- PL
- Poland
- Prior art keywords
- substances
- compounds
- obtaining
- formula
- conjugated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Lubricants (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1. Nowe zwiazki, pochodne hydrazonu o wzorze 1, w którym D oznacza ugrupowanie anty- biotyku antracyklinowego, takie jak adriamycy- na, a R oznacza grupe maleimidowa. Wzór 1 PL PL PL PL PL
Description
Przedmiotem wynalazku są nowe związki, pochodne hydrazonu. Nowe związki są związkami pośrednimi do wytwarzania koniugatów tioeterowych, które znajdują zastosowanie w leczeniu nowotworów.
Bifunkcjonalne związki, łączące reagenty cytotoksyczne z przeciwciałami są znane. Związki te są szczególnie użyteczne w tworzeniu immunokoniugatów skierowanych przeciwko antygenom nowotworowym. Takie immunokoniugaty pozwalają na selektywne dostarczanie toksycznych leków do komórek nowotworowych. (Patrz na przykład Hermentin i Seiler, nvestigations with Monoclonal Antibody Drug Coniugates, Behring. Insti. Mitl. 82:197-215 (1988); Gallego i wsp., '^i^^j^^r^tic^on of Four Daunomycin-Monoclonal Antibody 791T/36 Conjugates with Anti-Tumour Activity. Int. J. Cancer 33:737-44 (1984); Amon i wsp., In Vitro and In Vivo Efficacy of Conjugates of Daunomycin with Anti-Tumour Antibodies, Immunological Rev. 62:5-27 (1982).
Greenfield i wsp., opisali ostatnio tworzenie wrażliwych na kwas immunokoniugatów zawierających związek acylohydrazynowy, 3-(2-pirydyloditio)propionylohydrazyd, sprzężony poprzez wiązanie acylohydrazonowe z 13-keto pozycją cząsteczki antracykliny, oraz sprzęganie tych pochodnych antracykliny z cząsteczką przeciwciała (Greenfield i wsp., publikacja patentu europejskiego o numerze 328 147). Ujawniono również specyficzne łączniki oraz koniugaty zawierające ugrupowanie tioeterowe, w tym immunokoniugaty zawierające ugrupowanie hydrazono-tioeterowe.
Opisano również tworzenie koniugatów zawierających antybiotyki antracyklinowe przyłączone do bifunkcjonalnego łącznika poprzez wiązanie acylohydrazonowe w pozycji C-13 cząsteczki antracykliny. W ich wynalazku łączniki zawierają reaktywną grupę pirydynyloditio- lub orto-nitrofenyloditio, poprzez którą łącznik reaguje z odpowiednią grupą przyłączoną do ligandu reagującego z komórkami, tworząc gotowy koniugat.
Użyteczne byłoby uzyskanie dodatkowych związków, zawierających wrażliwe na działanie kwasu połączenie między cząsteczkami kierującą i reaktywną, do stosowania w terapii in vivo. Zatem wynalazek niniejszy dostarcza nowej chemii do łączenia aktywnych terapeutycznie cząsteczek leku z ligandem zdolnym do rozpoznawania wybranej populacji komórek celowych. Ta chemia łącznika stosowana jest następnie do wytworzenia aktywnych terapeutycznie koniugatów.
Każda cząsteczka leku jest połączona z ligandem poprzez zawierające ugrupowanie tioeterowe ramię łącznika. Lek jest przyłączony do tego łącznika poprzez wiązanie acylohydrazonowe. Wiązanie tioeterowe tworzy się przez reakcję grupy sulfhydrylowej z ligandu lub krótkiego ugrupowania przedłużacza przyłączonego do ligandu, z receptorem addycji Michaela, który po reakcji staje się adduktem Michaela. W korzystnej postaci ligand kierujący jest przyłączony bezpośrednio do łącznika poprzez kowalencyjne wiązanie tioeterowe.
Wynalazek dotyczy nowych związków, pochodnych hydrazonu o wzorze 1, w którym D oznacza ugrupowanie antybiotyku antracykllnowego, takiego jak adriamycyna, a R oznacza grupę maleimidową.
172 828
Korzystnie, pochodna hydrazonu ma postać związku o wzorze 2, w którym, Ri oznacza -CH2OH, R3 oznacza -OCH3, R4 oznacza -NH2, R5 oznacza -OH, Ró oznacza atom wodoru.
Ugrupowanie antracyklinowe, takie jak adriamycyna, jest związane z częścią łącznikową koniugatu poprzez wiązanie acylohydrazonowe w pozycji 13-keto związku antracyklinowego. Następnie do związku antracyklinowego jest przyłączone poprzez łącznik przeciwciało. W szczególnie korzystnej postaci łączenie to odbywa się poprzez zredukowaną grupę disiarczkową (to jest wolną grupę sulfhydrylową (-SH)) przeciwciała.
Antracyklinowym ugrupowaniem leku jest adriamycyna, receptorem addycji Michaela, z którego otrzymuje się addukt Michaela, jest grupa maleimidowa, a przeciwciałem jest przeciwciało BR96, BRó4, L6, chimeryczne przeciwciało BR96, BR64, L6, zrelaksowane przeciwciało BR96, BR64, L6, zrelaksowane przeciwciało chimeryczne BR96, BR64 lub L6, korzystnie chimeryczne przeciwciało BR96.
Koniugaty wytworzone z pochodnej hydrazonu według wynalazku zatrzymują zarówno specyficzność jak i aktywność leku terapeutycznego w działaniu na wybraną populację komórek celowych. Mogą być one stosowane w środkach farmaceutycznych, talach jak środki zawierające efektywną farmaceutycznie ilość związku o wzorze 1 w połączeniu z dopuszczalnym farmaceutycznie nośnikiem, rozcieńczalnikiem lub rozczynnikiem.
Dla wytworzenia hydrazonu według wynalazku, ugrupowanie antybiotyku antracyklinowego, takie jak adriamycyna, posiada dostępną do reakcji grupę karbonylową, taką jak na przykład reaktywne ugrupowanie aldehydowe lub ketonowe (przedstawiane tu jako [D-(C=0)j), zdolne do tworzenia hydrazonu (to jest połączenia -C=N-NH-). Hydrazonowe połączenie leku jest przedstawiane tu jako [D=]N-NH-. Ponadto korzystnie, reakcja tej dostępnej dla reakcji grupy z łącznikiem nie może zniszczyć końcowej aktywności terapeutycznej koniugatu, gdy aktywność ta jest wynikiem uwolnienia leku w pożądanym miejscu.
Dla specjalisty zrozumiałe jest, że dla tych leków, które nie posiadają dostępnej dla reakcji grupy karbonylowej może być otrzymana pochodna zawierająca taką grupę karbonylową przy zastosowaniu procedur znanych w stanie techniki. Należy wziąć pod uwagę, że pochodna leku musi zatrzymywać aktywność terapeutyczną w miejscu aktywnym. Alternatywnie, pochodna leku lub na przykład prolek musi być uwalniany w takiej formie, że przy miejscu aktywnym obecna jest aktywna terapeutycznie forma leku.
Łącznik może być stosowany w połączeniu z ugrupowaniem antracyklinowym, a więc z lekami przeciwbakteryjnymi i przeciwwirusowymi, przeciwgrzybiczymi, przeciwmikoplazmowymi i podobnych. Koniugaty leków otrzymane z nowych pochodnych hydrazonu są skuteczne dla zwykłych celów, dla których są skuteczne antybiotyki antracyklinowe, a ich efektywność jest lepsza dzięki właściwej dla ligandu zdolności transportowania leku do żądanej komórki, gdzie jest on szczególnie korzystny.
Nowe hydrazony według wynalazku znajdują zastosowanie jako leki cytotoksyczne, szczególnie leki stosowane w terapii nowotworów. W szczególności do użytecznych leków antracyklinowych należy na przykład adriamycyna.
Jak wspomniano poprzednio, specjalista może dokonać modyfikacji chemicznych żądanego związku tak, aby reakcje tego związku były bardziej dogodne dla celów wytwarzania pochodnych hydrazonu według wynalazku, a w dalszej kolejności koniugatów tioeterowych.
Stosowany antybiotyk antracyklinowy, taki jak adriamycyna, przedstawiony jest wzorem 3, w którym Ri oznacza -CH2OH, R3 oznacza -OCH3, R4 oznacza -NH2, R5 oznacza -OH, a Ró oznacza -H.
Jest zrozumiałe dla specjalisty, że w syntezie związków według wynalazku konieczne może być zabezpieczenie lub zablokowanie różnych reaktywnych grup funkcyjnych w związkach wyjściowych gdy reakcja pożądana jest prowadzona na innych częściach cząsteczki. Po zakończeniu pożądanych reakcji lub w każdym dowolnym czasie takie grupy zabezpieczające zwykle usuwa się na przykład przez hydrolizę lub hydrogenolizę. Takie etapy zabezpieczania i odbezpieczania są powszechnie stosowane w chemii organicznej. Wiadomości o grupach zabezpieczających, które mogą być użyteczne w wytwarzaniu związków według wynalazku są zamieszczone w książkach Protective Groups in Organic Che4
172 828 mistry, McOmie, ed., Plenum Press, N. Y., N. Y., (1973); i Protective Groups in Organic Synthesis, Greene, ed., John Wiley & Sons, New York, New York (1981).
Przykładowo do użytecznych grup zabezpieczających grupy aminowe należą grupy C1-C10 alkanoilowe takie jak formylowa, acetylowa, dichloroacetylowa, propionylowa, heksanoilowa, 3,3-dietyloheksanoilowa, γ-chlorobutyrylowa i podobne; grupy alkoksykarbonylowe C1-C10 i aryloksykarbonylowe C5-C15, takie jak tert-butoksykarbonylowa, benzyloksykarbonylowa, alliloksykarbonylowa, 4-nitrobenzyloksykarbonylowa i cynnamoiloksykarbonylowa; chlorowco-(C1-C10)-alkoksykarbonylowe, takie jak 2,2,2-trichloroetoksykarbonylowa; i grupy aryloalkilowe i alkenylowe C1-C15, takie jak benzylowa, fenetylowa, allilowa, tritylowa i podobne. Do innych grup powszechnie stosowanych jako grupy zabezpieczające grupy aminowe należą grupy w postaci enamin, otrzymanych z β-ketoestrów, takich jak acetooctan metylu lub etylu.
Podobnie do użytecznych grup zabezpieczających grupy hydroksylowe należą na przykład grupa formylowa, grupa chloroacetylowa, grupa benzylowa, grupa benzhydrylowa, grupa tritylowa, grupa 4-nitrobenzylowa, grupa trimetylosililowa, grupa fenacylowa, grupa tert-butylowa, grupa metoksymetylowa, grupa tetrahydropiranylowa i podobne.
Generalnie pochodną hydrazonową antracykliny o wzorze 1 lub 2, zawierającą receptor addycji Michaela otrzymuje się przez reakcję antybiotyku antracyklinowego (lub jego pochodnej) z hydrazydem zawierającym receptor addycji Michaela sposobem ogólnie przedstawionym na schemacie, na którym D i R mają znaczenia podane poprzednio.
Receptor addycji Michaela oznacza ugrupowanie, które jest zdolne do reagowania z reagentem nukleofilowym tak, aby zachodziła reakcja addycji nukleofilowej, charakterystyczna dla reakcji addycji Michaela. Jak wspomniano po zajściu addycji nukleofilowej ugrupowanie receptora addycji Michaela jest określane jako addukt Michaela.
Ogólne omówienie reakcji addycji Michaela zamieszczone jest w książkach E. D. Bergman, D. Ginsberg i R. Pappo, Org. React. 10,179-555 (1959); oraz w D. A. Oare i C. H. Heathcock, Topics in Stereochemistry, tom. 20, wyd., E. L. Eliel i S. H. Wilen, John Wiley and Sons, Inc. (1991) oraz w pozycjach literaturowych tam cytowanych.
Najbardziej korzystnym związkiem według wynalazku jest związek przedstawiony powyżej wzorem 2, w którym ugrupowaniem antybiotyku antracyklinowego jest andriamycyna, a receptorem addycji Michaela jest grupa maleimidowa. Po reakcji z ligandem (tiolowanym, modyfikowanym lub innym) maleimidowy receptor addycji Michaela staje się grupą sukcynoimidową (addukt Michaela) w końcowym koniugacie.
Hydrazon antracyklinowy o wzorze 1 wytwarza się przez reakcję antracykliny z hydrazydem maleimidokaproilowym lub jego solą. Reakcję generalnie prowadzi się w dwóch etapach. W etapie pierwszym wytwarza się hydrazyd maleimidokaproilowy lub jego sól. Po oczyszczeniu, na przykład przez chromatografię i/lub krystalizację, wolną zasadę hydrazydu lub jego sól poddaje się reakcji z żądaną antracykliną lub solą antracykliny. Po zatężeniu roztworu poreakcyjnego hydrazonowy produkt reakcji o wzorze 1 zawierający maleimid zbiera się i ewentualnie oczyszcza za pomocą standardowych technik oczyszczania.
Chociaż w poniższych przykładach przedstawiono specyficzne reagenty i warunki reakcji, to można dokonać modyfikacji, które są objęte istotą i zakresem wynalazku. Poniższe przykłady przedstawiono zatem w celu dodatkowego zilustrowania wynalazku.
Przykład I. Hydrazyd kwasu 2,5-dihydro-2,5-diokso-1H-piro!o-1-heksanowego i jego sól z kwasem trifluorooctowym (Hydrazyd maleimidokaproilowy)
Kwas maleimidokapronowy (2,11 g, 10 mmoli) [Patrz na przykład D. Rich et al., J. Med. Chem., 18,1004 (1975); i O. Keller et al., Helv. Chim. Acta, 58 531 (1975)] rozpuszczono w suchym tetrahydrofuranie (200 ml). Roztwór mieszano pod azotem, ochłodzono do 4°C i podziałano N-metylomorfoliną (1,01 g, 10 mmoli), po czym wkroplono roztwór chloromrówczanu izobutylu (1,36 g, 10 mmoli) w THF (10 ml). Po 5 minutach wkroplono roztwór karbazanu t-butylu (1,32 g, 10 mmoli) w THF (10 ml). Mieszaninę reakcyjną trzymano w 4°C przez pół godziny i w temperaturze pokojowej przez 1 godzinę. Rozpusz172 828 czalnik odparowano, a pozostałość podzielono między octan etylu i wodę. Warstwę organiczną przemyto rozcieńczonym roztworem HCl, wodą i rozcieńczonym roztworem wodorowęglanu, wysuszono nad bezwodnym siarczanem sodu i odparowano rozpuszczalnik. Materiał oczyszczono przez chromatografię podziałową przy użyciu gradientowego układu rozpuszczalników chlorek metylenu:metanol (100:1-2). Otrzymano zabezpieczony hydrazyd z wydajnością 70% (2,24 g).
Materiał ten (545 mg, 2,4 mmola) rozpuszczono i mieszano w kwasie trifluorooctowym w 0-4°C przez 8 minut. Kwas usunięto pod wysoką próżnią w temperaturze pokojowej. Pozostałość roztarto z eterem, otrzymując krystaliczną sól hydrazydu maleimidokaproilowego z kwasem trifluorooctowym (384 mg, 70%). Próbkę analityczną przygotowano przez krystalizację z układu metanol-eter, otrzymując produkt o tt. 102-105‘’C. NMR i MS były zgodne ze strukturą.
Analiza obliczona dla C10H15N3O3 · 0,8CF3COOH :
Obliczono: C, 44,02; H, 4,99; N, 13,28;
Znaleziono (analiza dwukrotna): C, 44,16, 44,13; H, 4,97, 5,00; N, 12,74,12,75.
Sól (220 mg) przekształcono w wolną zasadę przez chromatografię na żelu krzemionkowym przy użyciu układu rozpuszczalnikowego chlorek metylenu:metanol:stężony NH4OH (100:5:0,5). Otrzymany materiał (124 mg, 80%) krystalizowano z układu chlorek metylenu-eter, otrzymując produkt końcowy o tt. 92-93°C. NMR i MS były zgodne ze strukturą.
Analiza obliczona dla C10H15N3O3:
Obliczono: C, 53,33; H, 6,67; N, 18,67;
Znaleziono: C, 53,12; H, 6,67; N, 18,44.
Przykład II. Maleimidokaproilohydrazonadriamycyny
Mieszaninę chlorowodorku adriamycyny (44 mg, 0,075 mmola), hydrazydu maleimidokaproilowego (23 mg, 0,102 mmola), otrzymanego zgodnie z procedurą przedstawioną w przykładzie I i 2-3 krople kwasu trifluorooctowego w absolutnym metanolu (25 ml) mieszano przez 15 godzin pod azotem i zabezpieczono przed światłem. Pod koniec tego okresu nie wykrywano wolnej adriamycyny za pomocą HPLC (faza ruchoma 0,01 molowy roztwór octanu amonu:acetonitryl (70:30)). Roztwór zatężono w temperaturze pokojowej pod próżnią do 10 ml i rozcieńczono acetonitrylem. Przezroczysty roztwór zatężono do małej objętości, substancję stałą zebrano przez wirowanie, a produkt wysuszono pod wysoką próżnią, otrzymując związek tytułowy. NMR był zgodny ze strukturą. MS wysokiej rozdzielczości, obliczono dla C31H42N4O13: 751,2827; znaleziono 751,2804.
Hydrazon otrzymano również stosując adriamycynę i sól hydrazydu z kwasem trifluorooctowym. Zatem sól (40 mg, 0,12 mmola), otrzymaną zgodnie ze sposobem przedstawionym powyżej i chlorowodorek adriamycyny (50 mg, 0,086 mmola) mieszano w metanolu (30 ml) przez 15 godzin. Roztwór zatężono do 2 ml i rozcieńczono acetonitrylem. Czerwoną substancję stałą zebrano przez wirowanie i wysuszono pod próżnią. NMR i TLC produktu (28 mg, 43%) były identyczne jak dla produktu opisanego powyżej. MS wysokiej rozdzielczości, obliczono dla C31H42N4O13: 751,2827; znaleziono 751,2819.
172 828 [dJti-nhco/ch^-r
Wzór 1
“i Ϊ'
Wzór 2
172 828
+ hy® NH C0(CI^5 R-[!^WNHCXXCH2)gR
Schemat
Wzór 1
Departament Wydawnictw UP RP. Nakład 90 egz. Cena 2,00 zł
Claims (2)
- Zastrzeżenia patentowe1. Nowe związki, pochodne hydrazonu o wzorze 1, w którym D oznacza ugrupowanie antybiotyku antracyklinowego, takie jak adriamycyna, a R oznacza grupę maleimidową.
- 2. Związek według zastrz. 1, którym jest związek o wzorze 2, w którym R1 oznacza -CH2OH, R3 oznacza -OCH3, R4 oznacza -NH2, R5 oznacza -OH, R oznacza atom wodoru.* * *
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/824,951 US5622929A (en) | 1992-01-23 | 1992-01-23 | Thioether conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
PL297514A1 PL297514A1 (en) | 1993-08-23 |
PL172828B1 true PL172828B1 (pl) | 1997-12-31 |
Family
ID=25242736
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL93317715A PL172824B1 (pl) | 1992-01-23 | 1993-01-22 | Nowe koniugaty tioeterowe PL PL PL PL PL |
PL93317519A PL172715B1 (pl) | 1992-01-23 | 1993-01-22 | Sposób wytwarzania nowych koniugatów tioeterowych PL PL PL PL PL |
PL93317516A PL172718B1 (pl) | 1992-01-23 | 1993-01-22 | Sposób wytwarzania nowych koniugatów tioeterowych PL PL PL PL PL |
PL93297514A PL172828B1 (pl) | 1992-01-23 | 1993-01-22 | Nowe zwiazki, pochodne hydrazonu PL PL PL PL PL |
PL93317518A PL172827B1 (pl) | 1992-01-23 | 1993-01-22 | Nowe koniugaty tioeterowe PL PL PL PL PL |
PL93317517A PL172837B1 (pl) | 1992-01-23 | 1993-01-22 | Preparat farmaceutyczny zawierajacy koniugaty tioeterowe PL PL PL PL PL |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL93317715A PL172824B1 (pl) | 1992-01-23 | 1993-01-22 | Nowe koniugaty tioeterowe PL PL PL PL PL |
PL93317519A PL172715B1 (pl) | 1992-01-23 | 1993-01-22 | Sposób wytwarzania nowych koniugatów tioeterowych PL PL PL PL PL |
PL93317516A PL172718B1 (pl) | 1992-01-23 | 1993-01-22 | Sposób wytwarzania nowych koniugatów tioeterowych PL PL PL PL PL |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL93317518A PL172827B1 (pl) | 1992-01-23 | 1993-01-22 | Nowe koniugaty tioeterowe PL PL PL PL PL |
PL93317517A PL172837B1 (pl) | 1992-01-23 | 1993-01-22 | Preparat farmaceutyczny zawierajacy koniugaty tioeterowe PL PL PL PL PL |
Country Status (26)
Country | Link |
---|---|
US (3) | US5622929A (pl) |
EP (1) | EP0554708B9 (pl) |
JP (1) | JPH0625012A (pl) |
CN (3) | CN1040540C (pl) |
AT (1) | ATE294592T1 (pl) |
AU (1) | AU666903B2 (pl) |
BG (1) | BG61899B1 (pl) |
CA (1) | CA2087286C (pl) |
CZ (1) | CZ297409B6 (pl) |
DE (1) | DE69333800T2 (pl) |
DK (1) | DK0554708T3 (pl) |
EG (1) | EG20406A (pl) |
ES (1) | ES2240959T3 (pl) |
FI (1) | FI930240A (pl) |
HU (1) | HUT68345A (pl) |
IL (1) | IL104475A0 (pl) |
MX (1) | MX9300298A (pl) |
MY (1) | MY110526A (pl) |
NO (1) | NO930189L (pl) |
NZ (1) | NZ245725A (pl) |
OA (1) | OA09859A (pl) |
PL (6) | PL172824B1 (pl) |
RO (1) | RO112618B1 (pl) |
TW (1) | TW213921B (pl) |
UY (1) | UY23541A1 (pl) |
ZA (1) | ZA93444B (pl) |
Families Citing this family (495)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5637616A (en) * | 1993-06-18 | 1997-06-10 | Arcturus Pharmaceutical Corporation | Method for treating diseases mediated by proteases |
AU1140495A (en) * | 1994-01-27 | 1995-08-03 | Bristol-Myers Squibb Company | Method for preparing thioether conjugates |
US6544952B1 (en) | 1994-03-15 | 2003-04-08 | Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
US5708163A (en) * | 1994-03-15 | 1998-01-13 | Sloan-Kettering Institute Of Cancer Research | Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof |
US6303120B1 (en) * | 1994-03-15 | 2001-10-16 | Memorial Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the lewis y epitope and uses thereof |
US5599686A (en) * | 1994-06-28 | 1997-02-04 | Merck & Co., Inc. | Peptides |
US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US5907030A (en) * | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
US20030119724A1 (en) * | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
PT871490E (pt) * | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | Ligantes de hidrazona ramificada |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
SE9601158D0 (sv) * | 1996-03-26 | 1996-03-26 | Stefan Svenson | Method of producing immunogenic products and vaccines |
DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
JP2001505194A (ja) * | 1996-11-05 | 2001-04-17 | ブリストル―マイヤーズ・スクイブ・カンパニー | 分枝ペプチド・リンカー |
FR2766826B1 (fr) | 1997-08-04 | 2001-05-18 | Pasteur Institut | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules |
US6093692A (en) * | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
JP2002506625A (ja) | 1998-03-19 | 2002-03-05 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | サイトカインレセプター共通γ鎖様 |
EP1098666B1 (en) * | 1998-07-17 | 2013-01-16 | The United States of America, represented by the Secretary, Department of Health and Human Services | Water-soluble drugs and methods for their production |
CA2363779A1 (en) | 1999-02-26 | 2000-08-31 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
US6322980B1 (en) * | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
US7001725B2 (en) | 1999-04-30 | 2006-02-21 | Aclara Biosciences, Inc. | Kits employing generalized target-binding e-tag probes |
US6649351B2 (en) | 1999-04-30 | 2003-11-18 | Aclara Biosciences, Inc. | Methods for detecting a plurality of analytes by mass spectrometry |
US6673550B2 (en) | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
DE19926154A1 (de) * | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US7771929B2 (en) * | 2000-04-28 | 2010-08-10 | Monogram Biosciences, Inc. | Tag library compounds, compositions, kits and methods of use |
US7160735B2 (en) * | 2000-04-28 | 2007-01-09 | Monogram Biosciences, Inc. | Tagged microparticle compositions and methods |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
EP2431054A3 (en) | 2000-06-15 | 2013-03-06 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
PT2281843T (pt) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
MXPA03003401A (es) * | 2000-10-16 | 2004-06-30 | Neopharm Inc | Formulacion liposomica de mitoxantrona. |
TWI327600B (en) | 2000-11-28 | 2010-07-21 | Medimmune Llc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
WO2002043771A2 (en) | 2000-12-01 | 2002-06-06 | Cell Works Inc. | Conjugates of glycosylated/galactosylated peptide |
EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
EP1683865A3 (en) | 2001-02-02 | 2006-10-25 | Eli Lilly & Company | Mammalian proteins and in particular CD200 |
AU2002322478A1 (en) * | 2001-03-02 | 2002-12-16 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
CA2444632A1 (en) | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
EP1610751A4 (en) * | 2001-04-26 | 2006-05-24 | Univ Texas | AGENTE / LIGAND CONJUGATED THERAPEUTIC COMPOSITIONS, METHODS OF SYNTHESIS AND USE THEREOF |
ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
JP4309758B2 (ja) | 2001-05-25 | 2009-08-05 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Trailレセプターに免疫特異的に結合する抗体 |
EP1434778A4 (en) * | 2001-05-31 | 2005-07-13 | Medarex Inc | CYTOTOXINS, PROMEDICAMENTS, BINDERS AND STABILIZERS USEFUL THEREFOR |
US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
US7261875B2 (en) | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
RU2196604C1 (ru) * | 2001-12-21 | 2003-01-20 | Северин Евгений Сергеевич | Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе |
AU2003209340A1 (en) * | 2002-01-18 | 2003-09-02 | Bristol-Myers Squibb Company | Predictor sets for tyrosine kinase pathways |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US7591994B2 (en) * | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
US8361464B2 (en) | 2002-03-01 | 2013-01-29 | Immunomedics, Inc. | Anthracycline-Antibody Conjugates for Cancer Therapy |
US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
AU2003222253A1 (en) * | 2002-03-05 | 2003-09-22 | Monogram Biosciences, Inc. | Multiplex analysis using membrane-bound sensitizers |
AU2003218456A1 (en) * | 2002-04-01 | 2003-10-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
AU2003226065B2 (en) | 2002-04-12 | 2009-02-26 | Ludwig Institute For Cancer Research, Ltd | Recombinant anti-interleukin-9 antibodies |
JP4585968B2 (ja) | 2002-05-10 | 2010-11-24 | パーデュー・リサーチ・ファウンデーション | EphA2アゴニストモノクローナル抗体およびその使用法 |
US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
KR20050025669A (ko) * | 2002-07-25 | 2005-03-14 | 아클라라 바이오사이언시스 인코퍼레이티드 | 수용체 올리고머화의 검출 |
US7279585B2 (en) * | 2002-07-26 | 2007-10-09 | Monogram Biosciences, Inc. | Lipophilic electrophoretic probes |
ES2556641T3 (es) * | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
JP4596916B2 (ja) * | 2002-09-05 | 2010-12-15 | メディミューン,エルエルシー | Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法 |
EP2298806A1 (en) | 2002-10-16 | 2011-03-23 | Purdue Pharma L.P. | Antibodies that bind cell-associated CA 125/0722P and methods of use thereof |
US20040091850A1 (en) * | 2002-11-08 | 2004-05-13 | Travis Boone | Single cell analysis of membrane molecules |
US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
EP1572242B1 (en) * | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
MXPA05007615A (es) * | 2003-01-21 | 2005-09-30 | Bristol Myers Squibb Co | Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo. |
ES2457538T3 (es) | 2003-02-20 | 2014-04-28 | Seattle Genetics, Inc. | Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos |
CA2521826C (en) | 2003-04-11 | 2013-08-06 | Jennifer L. Reed | Recombinant il-9 antibodies and uses thereof |
US7402398B2 (en) * | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
AU2004286198C1 (en) | 2003-08-18 | 2011-02-24 | Medimmune, Llc | Humanization of antibodies |
US20050130246A1 (en) * | 2003-10-27 | 2005-06-16 | Hossein Salimi-Moosavi | Detecting human anti-therapeutic antibodies |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005058961A2 (en) * | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
GB0401008D0 (en) * | 2004-01-17 | 2004-02-18 | Univ Manchester | Drug delivery system |
US20050175619A1 (en) * | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
US7973139B2 (en) * | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
NZ550934A (en) * | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US7541330B2 (en) * | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
US7700720B2 (en) | 2004-09-21 | 2010-04-20 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
US7939267B2 (en) * | 2004-11-04 | 2011-05-10 | Laboratory Corporation Of America Holdings | Detection of activation of endothelial cells as surrogate marker for angiogenesis |
DK1827492T3 (da) | 2004-11-30 | 2010-11-22 | Curagen Corp | Antistoffer rettet mod GPNMB og anvendelser deraf |
KR20070115967A (ko) * | 2005-02-18 | 2007-12-06 | 메다렉스, 인코포레이티드 | 전립선 특이 막 항원(psma)에 대한 인간 모노클로날항체 |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
EP1869192B1 (en) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Framework-shuffling of antibodies |
CA2602849C (en) * | 2005-03-30 | 2013-06-04 | Saladax Biomedical Inc. | Doxorubicin immunoassay |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス, インコーポレイテッド | Il−31モノクローナル抗体とその使用法 |
AU2006261920A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Llc | Antibody formulations having optimized aggregation and fragmentation profiles |
WO2007008604A2 (en) * | 2005-07-08 | 2007-01-18 | Bristol-Myers Squibb Company | Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof |
US20070202512A1 (en) * | 2005-08-19 | 2007-08-30 | Bristol-Myers Squibb Company | Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof |
CA2623652C (en) * | 2005-09-26 | 2013-11-26 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
AU2006305842B2 (en) | 2005-10-26 | 2011-11-03 | E. R. Squibb & Sons, L.L.C. | Methods and compounds for preparing CC-1065 analogs |
CA2628238A1 (en) | 2005-11-07 | 2007-05-18 | The Scripps Research Institute | Compositions and methods for controlling tissue factor signaling specificity |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
US8575319B2 (en) * | 2006-03-10 | 2013-11-05 | The Regents Of The University Of California | Cleavable vaccine compositions and uses thereof and methods of making and using the same |
AU2007244683A1 (en) | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
WO2008019199A2 (en) | 2006-06-26 | 2008-02-14 | Macrogenics, Inc. | FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
PT2292663E (pt) | 2006-08-28 | 2013-11-04 | Kyowa Hakko Kirin Co Ltd | Anticorpos monoclonais humanos antagonistas específicos de light humano |
RU2009111884A (ru) | 2006-09-01 | 2010-10-10 | Займоджинетикс, Инк. (Us) | Последовательности вариабельных областей моноклональных антител против il-31 и способы использования |
AU2007313300A1 (en) | 2006-10-16 | 2008-04-24 | Medimmune, Llc. | Molecules with reduced half-lives, compositions and uses thereof |
US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
JP5276017B2 (ja) * | 2007-01-25 | 2013-08-28 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Egfr変異体仲介性疾患の治療における抗egfr抗体の使用 |
CA2678514A1 (en) | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Chemical linkers with single amino acids and conjugates thereof |
CN101688229B (zh) * | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途 |
EP2132312B1 (en) | 2007-03-27 | 2016-01-27 | Sea Lane Biotechnologies,llc. | Constructs and libraries comprising antibody surrogate light chain sequences |
JP5456658B2 (ja) | 2007-03-30 | 2014-04-02 | メディミューン,エルエルシー | 抗体製剤 |
US10280211B2 (en) | 2007-05-04 | 2019-05-07 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Engineered rabbit antibody variable domains and uses thereof |
MX2009012341A (es) | 2007-05-14 | 2010-02-17 | Medimmune Llc | Metodos para reducir niveles de eosinofilos. |
BRPI0811248A2 (pt) * | 2007-05-16 | 2014-11-04 | Ktb Tumorforschungs Gmbh | Formulação de antraciclina de baixa viscosidade. |
PE20090481A1 (es) | 2007-07-16 | 2009-05-18 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
RS52305B (en) | 2007-07-16 | 2012-12-31 | Genentech Inc. | ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE |
CN101896503B (zh) | 2007-08-14 | 2018-05-22 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
CA2697992C (en) | 2007-10-04 | 2017-08-22 | Zymogenetics, Inc. | B7 family member zb7h6 and related compositions and methods |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
ME03057B (me) | 2007-12-07 | 2019-01-20 | Zymogenetics Inc | Molekuli humanizovanih antitela specifični za il-31 |
EP2235536A4 (en) * | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2 DIAGNOSTIC METHODS |
KR20100107501A (ko) | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | 부위 특이적 접합을 위한 시스테인 조작 항체 |
ES2587392T3 (es) | 2008-01-31 | 2016-10-24 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
EP2837388A1 (en) | 2008-08-05 | 2015-02-18 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
CA2764386C (en) | 2008-12-01 | 2018-05-01 | Laboratory Corporation Of America Holdings | P95-her2 antibodies and uses thereof |
SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
EP2396035A4 (en) | 2009-02-12 | 2012-09-12 | Human Genome Sciences Inc | USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE |
HUE062339T2 (hu) | 2009-02-13 | 2023-10-28 | Immunomedics Inc | Sejten belül hasítható kötést tartalmazó immunkonjugátumok |
CN102482345A (zh) | 2009-05-13 | 2012-05-30 | 航道生物技术有限责任公司 | 针对流感病毒的中和分子 |
DK2437767T3 (en) | 2009-06-01 | 2015-09-28 | Medimmune Llc | MOLECULES WITH EXTENDED half-lives and uses thereof |
WO2011005481A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
ES2629167T3 (es) | 2009-07-20 | 2017-08-07 | Bristol-Myers Squibb Company | Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas |
EP2464657B1 (en) | 2009-08-10 | 2015-04-01 | MorphoSys AG | Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity |
EA023179B1 (ru) | 2009-08-13 | 2016-05-31 | Круселл Холланд Б.В. | Антитела против респираторного синцитиального вируса (pcb) и способы их применения |
CA2769822C (en) | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011035205A2 (en) | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
EA030827B1 (ru) | 2009-10-23 | 2018-10-31 | Милленниум Фармасьютикалз, Инк. | Анти-gcc антитело и его применения |
JP2013513380A (ja) | 2009-12-09 | 2013-04-22 | アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・(イ・エヌ・エス・ウ・エール・エム) | B7h6と結合するモノクローナル抗体およびその使用 |
WO2011097627A1 (en) | 2010-02-08 | 2011-08-11 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 161p2f10b proteins |
SG185415A1 (en) | 2010-05-06 | 2012-12-28 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
ES2659406T3 (es) | 2010-05-06 | 2018-03-15 | Novartis Ag | Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6) |
MX356527B (es) | 2010-07-09 | 2018-06-01 | Bioverativ Therapeutics Inc | Polipeptidos de factor ix y metodos para usarlos. |
MX343298B (es) | 2010-07-09 | 2016-11-01 | Crucell Holland Bv | Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso. |
US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
WO2012016227A2 (en) | 2010-07-29 | 2012-02-02 | Xencor, Inc. | Antibodies with modified isoelectric points |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
JP6057896B2 (ja) | 2010-08-20 | 2017-01-11 | ノバルティス アーゲー | 上皮細胞増殖因子受容体3(her3)に対する抗体 |
MX2013002255A (es) | 2010-08-27 | 2013-07-03 | Stem Centrx Inc | Moduladores de proteina de notum y metodos de uso. |
WO2012031273A2 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Novel modulators and methods of use |
AU2011312417B2 (en) | 2010-09-29 | 2015-08-20 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
CN103533957B (zh) | 2010-12-06 | 2016-06-22 | 西雅图遗传学公司 | 抗liv-1的人源化抗体及其在治疗癌症中的用途 |
RU2016123839A (ru) | 2010-12-08 | 2018-11-30 | АббВай Стемсентркс ЭлЭлСи | Новые модуляторы и способы их применения |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
SG194609A1 (en) | 2011-05-19 | 2013-12-30 | Lab Corp America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
DK3415531T3 (da) | 2011-05-27 | 2023-09-18 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17)-bindende proteiner |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
WO2013016714A1 (en) | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies | Sur-binding proteins against erbb3 |
WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
WO2013043071A1 (en) | 2011-09-23 | 2013-03-28 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
DK2766392T3 (da) | 2011-10-10 | 2019-10-07 | Xencor Inc | Fremgangsmåde til oprensning af antistoffer |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
CN103071159B (zh) * | 2011-10-25 | 2014-10-15 | 天津药物研究院 | 一种阿霉素-多肽复合物、药物组合物的制备方法和应用 |
EP2773373B1 (en) | 2011-11-01 | 2018-08-22 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
AU2012332593B2 (en) | 2011-11-01 | 2016-11-17 | Bionomics, Inc. | Anti-GPR49 antibodies |
US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
EP2773665A1 (en) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Antibodies and methods of treating cancer |
ES2666856T3 (es) | 2011-11-04 | 2018-05-08 | Novartis Ag | Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media |
PL2773671T3 (pl) | 2011-11-04 | 2022-01-24 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc |
JP2015505828A (ja) | 2011-12-02 | 2015-02-26 | イーライ リリー アンド カンパニー | 抗グルカゴン抗体およびその使用 |
CN108341873B (zh) | 2011-12-05 | 2022-03-25 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
WO2013084148A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
KR102159843B1 (ko) | 2011-12-21 | 2020-09-24 | 노파르티스 아게 | 인자 p를 표적화하는 항체에 대한 조성물 및 방법 |
CA2859744A1 (en) | 2011-12-22 | 2013-06-27 | Sea Lane Biotechnologies, Llc | Surrogate binding proteins |
US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
WO2013109994A1 (en) | 2012-01-20 | 2013-07-25 | Sea Lane Biotechnologies, Llc | Surrobody cojugates |
MX2014010094A (es) | 2012-02-24 | 2014-09-16 | Stem Centrx Inc | Anticuerpos anti-homologo relacionado con las convulsiones 6 (anti-sez6) y metodos de uso. |
RU2014138474A (ru) | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
KR102057356B1 (ko) | 2012-02-27 | 2019-12-18 | 아뮤닉스 파마슈티컬스, 인크. | Xten 콘주게이트 조성물 및 그의 제조 방법 |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
WO2013166594A1 (en) | 2012-05-10 | 2013-11-14 | Zymeworks Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain |
KR102144069B1 (ko) | 2012-05-15 | 2020-08-13 | 시애틀 지네틱스, 인크. | 자가-안정화 링커 접합체 |
CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
SG11201501286PA (en) | 2012-08-23 | 2015-05-28 | Agensys Inc | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
WO2014053479A1 (en) | 2012-10-02 | 2014-04-10 | Roche Diagnostics Gmbh | Methods of specifically releasing a sub-group of objects |
JP2015533832A (ja) | 2012-10-09 | 2015-11-26 | アイジェニカ バイオセラピューティクス インコーポレイテッド | 抗C16orf54抗体およびその使用方法 |
ES2701076T3 (es) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células |
WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
US9365646B2 (en) | 2012-12-05 | 2016-06-14 | Novartis Ag | Compositions and methods for antibodies targeting EPO |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
JP6366111B2 (ja) | 2012-12-13 | 2018-08-01 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 有効性の改善および毒性の減少のための、抗体およびsn−38からなるイムノコンジュゲートの投薬 |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
UY35195A (es) | 2012-12-18 | 2014-07-31 | Novartis Ag | Composiciones y metodos para proteinas de accion prolongada |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
AU2014207549B2 (en) | 2013-01-15 | 2018-12-06 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
WO2014124227A1 (en) | 2013-02-07 | 2014-08-14 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
SG11201506650PA (en) | 2013-02-22 | 2015-09-29 | Stemcentrx Inc | Novel antibody conjugates and uses thereof |
IL275376B2 (en) | 2013-03-11 | 2024-01-01 | Genzyme Corp | Polypeptides with hyperglycosidic bonds |
SI2970473T1 (sl) | 2013-03-14 | 2017-10-30 | Bristol-Myers Squibb Company | Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe |
EP2970479B1 (en) | 2013-03-14 | 2019-04-24 | Novartis AG | Antibodies against notch 3 |
SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
PL2968440T3 (pl) | 2013-03-15 | 2019-12-31 | Zymeworks Inc. | Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania |
CA2906927C (en) | 2013-03-15 | 2021-07-13 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
CA2902739C (en) | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US20160041171A1 (en) | 2013-04-05 | 2016-02-11 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
US10100123B2 (en) | 2013-06-06 | 2018-10-16 | Pierre Fabre Medicament | Anti-C10orf54 antibodies and uses thereof |
UY35620A (es) | 2013-06-21 | 2015-01-30 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
AR096601A1 (es) | 2013-06-21 | 2016-01-20 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US9925273B2 (en) | 2013-08-01 | 2018-03-27 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to CD37 proteins |
KR102362630B1 (ko) | 2013-08-26 | 2022-02-15 | 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 | 시알릴-루이스 a에 대한 사람 항체 코드화 핵산 |
JP2016538318A (ja) | 2013-08-28 | 2016-12-08 | ステムセントリックス, インコーポレイテッド | 新規sez6モジュレーターおよび使用方法 |
MX2016002547A (es) | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones. |
WO2015054691A2 (en) | 2013-10-11 | 2015-04-16 | The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services | Tem8 antibodies and their use |
CR20160156A (es) | 2013-10-11 | 2016-11-01 | Oxford Biotherapeutics Ltd | Anticuerpos conjugados contra ly75 para el tratamiento del cáncer |
KR20240034882A (ko) | 2013-10-15 | 2024-03-14 | 씨젠 인크. | 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커 |
EP3065780A1 (en) | 2013-11-04 | 2016-09-14 | Pfizer Inc. | Anti-efna4 antibody-drug conjugates |
EP3066118B1 (en) | 2013-11-06 | 2020-01-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
DK3074036T3 (da) | 2013-11-25 | 2019-11-18 | Seattle Genetics Inc | Fremstilling af antistoffer ud fra CHO-cellekulturer til konjugation. |
EP3086815B1 (en) | 2013-12-27 | 2022-02-09 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2015103989A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for immunotherapy |
MX2016009555A (es) | 2014-01-24 | 2016-12-08 | Ngm Biopharmaceuticals Inc | Proteinas de union y metodos para utilizarlas. |
US10308721B2 (en) | 2014-02-21 | 2019-06-04 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
CN116333148A (zh) | 2014-03-19 | 2023-06-27 | 建新公司 | 靶向模块的位点特异性糖工程化 |
UY36041A (es) | 2014-03-21 | 2015-09-30 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr |
US10300070B2 (en) | 2014-03-27 | 2019-05-28 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
ME03666B (me) | 2014-03-28 | 2020-10-20 | Xencor Inc | Bispecifična antitela koja se vezuju za cd38 i cd3 |
JP6614582B2 (ja) | 2014-04-04 | 2019-12-04 | バイオノミクス インコーポレイテッド | Lgr5に結合するヒト化抗体 |
WO2015175375A1 (en) | 2014-05-13 | 2015-11-19 | Short Jay M | Conditionally active biological proteins |
CN106413750B (zh) | 2014-05-16 | 2022-04-29 | 免疫医疗有限责任公司 | 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子 |
KR102614642B1 (ko) | 2014-06-04 | 2023-12-19 | 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 | 강글리오사이드 gd2에 대한 사람 단클론 항체 |
EP3797768A1 (en) | 2014-06-23 | 2021-03-31 | Placon Therapeutics, Inc. | Maleimide-functionalised platinum for use in the treatment of cancer |
EP3160991A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Compositions and methods for long acting proteins |
EP3161001A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
US20170290876A1 (en) | 2014-06-25 | 2017-10-12 | Novartis Ag | Compositions and methods for long acting proteins |
WO2016014984A1 (en) | 2014-07-24 | 2016-01-28 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
CA2955007C (en) * | 2014-07-24 | 2023-04-11 | Genentech, Inc. | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
EP3194437B1 (en) | 2014-08-07 | 2021-01-20 | Novartis AG | Angiopoietin-like 4 (angptl4) antibodies and methods of use |
DK3177642T3 (da) | 2014-08-07 | 2022-02-21 | Novartis Ag | Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf |
CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
WO2016036916A1 (en) | 2014-09-03 | 2016-03-10 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
RS62860B1 (sr) | 2014-09-17 | 2022-02-28 | Zymeworks Inc | Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih |
EP3262071B8 (en) | 2014-09-23 | 2022-05-18 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CA2964123C (en) | 2014-10-09 | 2023-09-05 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
SI3221349T1 (sl) | 2014-11-19 | 2021-02-26 | Axon Neuroscience Se | Humanizirano tau protitelo pri alzheimerjevi bolezni |
EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
KR20170084327A (ko) | 2014-11-26 | 2017-07-19 | 젠코어 인코포레이티드 | Cd3 및 cd38에 결합하는 이형이량체 항체 |
DK3229838T3 (da) | 2014-12-11 | 2020-10-19 | Pf Medicament | Anti-C10orf54-antistoffer og anvendelser deraf |
UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
HRP20230046T1 (hr) | 2015-03-03 | 2023-03-03 | Kymab Limited | Protutijela, upotreba i postupci |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
EP3265474A1 (en) | 2015-03-05 | 2018-01-10 | Sirenas LLC | Cyclic peptide analogs and conjugates thereof |
UA122331C2 (uk) | 2015-03-09 | 2020-10-26 | Едженсіс, Інк. | Антитіло проти flt3 та кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком flt3 |
US9797907B2 (en) | 2015-04-22 | 2017-10-24 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
KR20180002782A (ko) | 2015-05-06 | 2018-01-08 | 얀센 바이오테크 인코포레이티드 | 전립선 특이적 막 항원(psma) 이중특이성 결합제 및 그의 용도 |
EP3091033A1 (en) | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
MX2017015690A (es) | 2015-06-05 | 2018-07-06 | Novartis Ag | Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos. |
JP7269733B2 (ja) | 2015-06-12 | 2023-05-09 | レンティジェン・テクノロジー・インコーポレイテッド | 操作されたt細胞を用いて癌を処置するための方法 |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
JP6879947B2 (ja) | 2015-06-30 | 2021-06-02 | シージェン インコーポレイテッド | 抗ntb−a抗体及び関連組成物ならびに方法 |
EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
NZ739830A (en) | 2015-07-12 | 2021-12-24 | Hangzhou Dac Biotech Co Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
EP3331914A1 (en) | 2015-08-03 | 2018-06-13 | Novartis AG | Methods of treating fgf21-associated disorders |
DK3347377T3 (da) | 2015-09-09 | 2021-05-10 | Novartis Ag | Tymisk stromal lymfopoietin (TSLP)-bindende antistoffer og fremgangsmåder til anvendelse af antistofferne |
AU2016320748B2 (en) | 2015-09-09 | 2019-05-02 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies |
EP3347047A1 (en) | 2015-09-09 | 2018-07-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Expression vector delivery system and use thereof for inducing an immune response |
KR20180054824A (ko) | 2015-09-29 | 2018-05-24 | 셀진 코포레이션 | Pd-1 결합 단백질 및 이의 사용 방법 |
US10392441B2 (en) | 2015-10-07 | 2019-08-27 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
EP3359562B1 (en) | 2015-10-09 | 2019-12-04 | Miltenyi Biotec Technology, Inc. | Chimeric antigen receptors and methods of use |
WO2017066714A1 (en) | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
EP3371349A1 (en) | 2015-11-02 | 2018-09-12 | Bioatla, LLC | Conditionally active polypeptides |
AU2016362777B2 (en) | 2015-12-04 | 2020-01-30 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Cd3及びpsmaに結合するヘテロ二量体抗体 |
CN109069623A (zh) | 2015-12-18 | 2018-12-21 | 诺华股份有限公司 | 靶向CD32b的抗体及其使用方法 |
EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
US20170224837A1 (en) | 2016-02-10 | 2017-08-10 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
EP3419655A1 (en) | 2016-02-27 | 2019-01-02 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Peptide vaccines comprising self-assembling polymer nanoparticles |
AU2017225982B2 (en) | 2016-03-02 | 2023-10-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
MA45324A (fr) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
CN108780089B (zh) | 2016-03-15 | 2020-09-08 | 美国控股实验室公司 | 评估细胞间的蛋白质相互作用的方法 |
JP2019509322A (ja) | 2016-03-22 | 2019-04-04 | バイオノミクス リミテッド | 抗lgr5モノクローナル抗体の投与 |
EP3433278A4 (en) | 2016-03-25 | 2019-11-06 | Seattle Genetics, Inc. | PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINE LINKS AND INTERMEDIATES THEREOF |
AU2017254674A1 (en) | 2016-04-21 | 2018-11-01 | Abbvie Stemcentrx Llc | Novel anti-BMPR1B antibodies and methods of use |
WO2017189483A1 (en) | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
WO2017189724A1 (en) | 2016-04-27 | 2017-11-02 | Novartis Ag | Antibodies against growth differentiation factor 15 and uses thereof |
RU2725292C2 (ru) | 2016-04-27 | 2020-06-30 | Иммьюномедикс, Инк. | Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей |
TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
WO2017214339A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
CN109562169A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
CN116284404A (zh) | 2016-06-08 | 2023-06-23 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
WO2017214322A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
AU2017277916A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-CD98 antibodies and antibody drug conjugates |
RU2022104399A (ru) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
CA3027651A1 (en) | 2016-06-15 | 2017-12-21 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) |
US10316088B2 (en) | 2016-06-28 | 2019-06-11 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
WO2018005678A1 (en) | 2016-06-29 | 2018-01-04 | The Regents Of The University Of California | Compounds and compositions for the treatment of cancer |
US11479601B2 (en) | 2016-06-29 | 2022-10-25 | The Regents Of The University Of California | Antibodies specific to Sonic Hedgehog and method of use thereof |
CN109641968B (zh) | 2016-07-06 | 2023-10-20 | 百时美施贵宝公司 | Tim-4拮抗剂和pd-1拮抗剂的组合及其使用方法 |
KR20190038579A (ko) | 2016-08-09 | 2019-04-08 | 시애틀 지네틱스, 인크. | 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CN109843922B (zh) | 2016-09-02 | 2023-10-03 | 莱蒂恩技术公司 | 用DuoCAR治疗癌症的组合物和方法 |
WO2018045245A1 (en) | 2016-09-02 | 2018-03-08 | Sirenas Llc | Cyclic peptide analogs and conjugates thereof |
EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
KR102562519B1 (ko) | 2016-10-14 | 2023-08-02 | 젠코어 인코포레이티드 | IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질 |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US20210308277A1 (en) | 2016-11-14 | 2021-10-07 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers |
CN110325211A (zh) | 2016-12-23 | 2019-10-11 | 诺华股份有限公司 | 采用抗因子XI/XIa抗体治疗的方法 |
CN110325550B (zh) | 2016-12-23 | 2024-03-08 | 诺华股份有限公司 | 因子xi抗体和使用方法 |
EP3565830B1 (en) | 2017-01-09 | 2021-03-10 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-mesothelin immunotherapy |
EP3574016A2 (en) | 2017-01-24 | 2019-12-04 | Innate Pharma | NKp46 BINDING AGENTS |
US20200023071A1 (en) | 2017-02-06 | 2020-01-23 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
AU2018218557B9 (en) | 2017-02-08 | 2021-06-24 | Novartis Ag | FGF21 mimetic antibodies and uses thereof |
US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
WO2018175988A1 (en) | 2017-03-24 | 2018-09-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd33 immunotherapy |
JP2020512314A (ja) | 2017-03-27 | 2020-04-23 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | サシツズマブゴビテカンとRAD51阻害剤を用いたTrop−2発現トリプルネガティブ乳癌の治療 |
CA3044082A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
CA3057715A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
US20230190796A1 (en) | 2017-04-07 | 2023-06-22 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
US11932694B2 (en) | 2017-04-19 | 2024-03-19 | Bluefin Biomedicine, Inc. | Anti-VTCN1 antibodies and antibody drug conjugates |
WO2018199337A1 (ja) | 2017-04-28 | 2018-11-01 | 味の素株式会社 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
EP3630162A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
AU2018274216A1 (en) | 2017-05-24 | 2019-12-12 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
MA49517A (fr) | 2017-06-30 | 2020-05-06 | Xencor Inc | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
WO2019014044A1 (en) | 2017-07-12 | 2019-01-17 | The Johns Hopkins University | ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES |
AU2018309735A1 (en) | 2017-07-31 | 2020-02-20 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy |
US20190048049A1 (en) | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding Sa | Cargomers |
JP7035170B2 (ja) | 2017-09-15 | 2022-03-14 | レンティジェン・テクノロジー・インコーポレイテッド | 抗cd19免疫療法によりがんを処置するための組成物および方法 |
JP7256796B2 (ja) | 2017-10-13 | 2023-04-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Thomsen-nouvelle(tn)抗原に対するヒト抗体 |
WO2019079249A1 (en) | 2017-10-16 | 2019-04-25 | Lentigen Technology, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY |
JP7381478B2 (ja) | 2017-10-23 | 2023-11-15 | マブリンク ビオシオンス | 単一分子量ポリサルコシンを含むリガンド-薬物-複合体 |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
KR20200085828A (ko) | 2017-11-08 | 2020-07-15 | 젠코어 인코포레이티드 | 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체 |
EP3717518A1 (en) | 2017-12-01 | 2020-10-07 | Seattle Genetics, Inc. | Humanized anti-liv1 antibodies for the treatment of breast cancer |
KR20200091901A (ko) | 2017-12-01 | 2020-07-31 | 시애틀 지네틱스, 인크. | 암을 치료하기 위한 cd47 항체 및 이의 용도 |
MX2020006322A (es) | 2017-12-19 | 2020-09-18 | Xencor Inc | Proteinas de fusion il-2 fc modificadas. |
US10894819B2 (en) | 2017-12-20 | 2021-01-19 | Lentigen Technology, Inc. | Compositions and methods for treating HIV/AIDS with immunotherapy |
WO2019129054A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
US11807663B2 (en) | 2018-02-01 | 2023-11-07 | Innovent Biologics (Suzhou) Co., Ltd. | Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof |
EP3768324A1 (en) | 2018-03-22 | 2021-01-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy |
SG11202009264WA (en) | 2018-03-23 | 2020-10-29 | Seattle Genetics Inc | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
WO2019184909A1 (zh) | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
SG11202008098TA (en) | 2018-03-28 | 2020-10-29 | Axon Neuroscience Se | Antibody-based methods of detecting and treating alzheimer's disease |
AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
WO2019204665A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
EP3796943A2 (en) | 2018-05-22 | 2021-03-31 | Avidea Technologies, Inc. | Improved methods of manufacturing peptide-based vaccines |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
WO2019232449A1 (en) | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use |
CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
AU2019285354A1 (en) | 2018-06-14 | 2021-01-07 | Ajinomoto Co., Inc. | Substance having affinity for antibody, and compound or salt thereof having bioorthogonal functional group |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
JP7413999B2 (ja) | 2018-06-14 | 2024-01-16 | 味の素株式会社 | 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
JOP20200343A1 (ar) | 2018-07-02 | 2020-12-31 | Xencor Inc | بروتين ربط مولد ضد مضاد لـ steap1 |
WO2020016459A1 (en) | 2018-07-20 | 2020-01-23 | Pierre Fabre Medicament | Receptor for vista |
WO2020061498A1 (en) | 2018-09-20 | 2020-03-26 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd123 immunotherapy |
CN113286607A (zh) | 2018-09-26 | 2021-08-20 | 莱蒂恩技术公司 | 用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法 |
WO2020072681A1 (en) | 2018-10-03 | 2020-04-09 | Avidea Technologies, Inc. | Aromatic ring substituted amphiphilic polymers as drug delivery systems |
CA3115096A1 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
CN113227124A (zh) | 2018-10-31 | 2021-08-06 | 味之素株式会社 | 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐 |
US11103533B2 (en) | 2018-11-30 | 2021-08-31 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD38 immunotherapy |
KR20210102274A (ko) | 2018-12-13 | 2021-08-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 헤르복시디엔 항체-약물 접합체 및 사용 방법 |
EP3920968A1 (en) | 2019-02-05 | 2021-12-15 | Seagen Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
US11472890B2 (en) | 2019-03-01 | 2022-10-18 | Xencor, Inc. | Heterodimeric antibodies that bind ENPP3 and CD3 |
CN113924103A (zh) | 2019-03-06 | 2022-01-11 | 莱蒂恩技术公司 | 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法 |
WO2020191344A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
KR20210154158A (ko) | 2019-03-20 | 2021-12-20 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 클라우딘-6 항체 및 약물 컨쥬게이트 |
US20220169706A1 (en) | 2019-03-28 | 2022-06-02 | Danisco Us Inc | Engineered antibodies |
WO2020214858A1 (en) | 2019-04-17 | 2020-10-22 | Avidea Technologies, Inc. | Compositions and methods of manufacturing star polymers for ligand display and/or drug delivery |
EP3958908A1 (en) | 2019-04-24 | 2022-03-02 | Heidelberg Pharma Research GmbH | Amatoxin antibody-drug conjugates and uses thereof |
PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
EP3972993A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Variant cd58 domains and uses thereof |
CN114364801B (zh) | 2019-05-30 | 2024-04-19 | 莱蒂恩技术公司 | 用于用抗bcma免疫治疗来治疗癌症的组合物和方法 |
US20220233709A1 (en) | 2019-06-05 | 2022-07-28 | Seagen Inc. | Masked Antibody Formulations |
TW202112801A (zh) | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 純化遮蔽抗體之方法 |
CA3142833A1 (en) | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
KR20220035486A (ko) | 2019-07-22 | 2022-03-22 | 씨젠 인크. | 암 치료를 위한 인간화 항-liv1 항체 |
CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
JP2022550434A (ja) | 2019-10-04 | 2022-12-01 | ティーエーイー ライフ サイエンシーズ | Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物 |
BR112022005114A2 (pt) | 2019-10-04 | 2022-06-21 | Seagen Inc | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco |
EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
WO2021116119A1 (en) | 2019-12-09 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
EP4087657A1 (en) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
US20230203191A1 (en) | 2020-03-30 | 2023-06-29 | Danisco Us Inc | Engineered antibodies |
EP4143236A1 (en) | 2020-05-01 | 2023-03-08 | Novartis AG | Engineered immunoglobulins |
WO2021220218A1 (en) | 2020-05-01 | 2021-11-04 | Novartis Ag | Immunoglobulin variants |
WO2021224186A1 (en) | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
WO2021228956A1 (en) | 2020-05-12 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
IL298053A (en) | 2020-06-05 | 2023-01-01 | Eisai R&D Man Co Ltd | Antibody-drug conjugates against bcma and methods of use |
WO2021251358A1 (ja) | 2020-06-09 | 2021-12-16 | 味の素株式会社 | 修飾フェリチンおよびその製造方法 |
AU2021296423A1 (en) | 2020-06-22 | 2023-02-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy |
AU2021320739A1 (en) | 2020-08-04 | 2023-02-23 | Seagen Inc. | Anti-CD228 antibodies and antibody-drug conjugates |
EP3970752A1 (en) | 2020-09-17 | 2022-03-23 | Merck Patent GmbH | Molecules with solubility tag and related methods |
AU2021347147A1 (en) | 2020-09-22 | 2023-05-18 | Barinthus Biotherapeutics North America, Inc. | Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ |
MX2023003404A (es) | 2020-09-28 | 2023-03-31 | Seagen Inc | Anticuerpos anti-l1vi humanizados para el tratamiento del cancer. |
IL301769A (en) | 2020-10-01 | 2023-05-01 | Abionyx Pharma Sa | Methods for treating eye diseases by using complexes based on lipid-binding proteins |
EP4228701A1 (en) | 2020-10-19 | 2023-08-23 | Vaccitech North America, Inc. | Star polymer drug conjugates |
WO2022084325A1 (en) | 2020-10-20 | 2022-04-28 | Institut Curie | Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer |
EP4240397A1 (en) | 2020-11-05 | 2023-09-13 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
EP4240491A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19 binding molecules and uses thereof |
EP4271482A2 (en) | 2020-12-31 | 2023-11-08 | Alamar Biosciences, Inc. | Binder molecules with high affinity and/ or specificity and methods of making and use thereof |
AU2022208654A1 (en) | 2021-01-18 | 2023-08-03 | Ajinomoto Co., Inc. | Compound or salt thereof, and antibody produced using same |
WO2022154127A1 (ja) | 2021-01-18 | 2022-07-21 | 味の素株式会社 | 化合物またはその塩、およびそれらにより得られる抗体 |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
CA3207998A1 (en) | 2021-02-16 | 2022-08-25 | Geoffrey M. Lynn | Self-assembling nanoparticles based on amphiphilic peptides |
CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
CN116964076A (zh) | 2021-03-11 | 2023-10-27 | 味之素株式会社 | 化合物或其盐、以及由它们得到的抗体 |
WO2022189618A1 (en) | 2021-03-12 | 2022-09-15 | Institut Curie | Nitrogen-containing heterocycles as radiosensitizers |
EP4310096A1 (en) | 2021-03-16 | 2024-01-24 | Ajinomoto Co., Inc. | Complex or salt thereof, and method for manufacturing same |
JP2024512478A (ja) | 2021-03-19 | 2024-03-19 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bリンパ球特異的アマトキシン抗体コンジュゲート |
WO2022211508A1 (ko) | 2021-03-30 | 2022-10-06 | 주식회사 레고켐바이오사이언스 | 인간 cldn18.2에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
CN117279664A (zh) | 2021-04-10 | 2023-12-22 | 普方生物制药美国公司 | Folr1结合剂、其偶联物及其使用方法 |
WO2022219413A1 (en) | 2021-04-15 | 2022-10-20 | Abionyx Pharma Sa | Use of lipid binding protein-based complexes in organ preservation solutions |
EP4326768A1 (en) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023288236A1 (en) | 2021-07-14 | 2023-01-19 | Seagen Inc. | Antibody masking domains |
WO2023049825A1 (en) | 2021-09-24 | 2023-03-30 | Seagen Inc. | Improved antibody masking domains |
CA3234692A1 (en) | 2021-09-30 | 2023-04-06 | Ajinomoto Co., Inc. | Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof |
WO2023089314A1 (en) | 2021-11-18 | 2023-05-25 | Oxford Biotherapeutics Limited | Pharmaceutical combinations |
WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
TW202337904A (zh) | 2022-01-07 | 2023-10-01 | 美商壯生和壯生企業創新公司 | IL-1β結合蛋白之材料及方法 |
US11590169B1 (en) | 2022-03-02 | 2023-02-28 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD123 immunotherapy |
US20230338424A1 (en) | 2022-03-02 | 2023-10-26 | Lentigen Technology, Inc. | Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
WO2023194797A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
US20230355792A1 (en) | 2022-04-07 | 2023-11-09 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index |
TW202400658A (zh) | 2022-04-26 | 2024-01-01 | 瑞士商諾華公司 | 靶向il—13和il—18的多特異性抗體 |
WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
WO2024026107A2 (en) | 2022-07-28 | 2024-02-01 | Lentigen Technology, Inc. | Chimeric antigen receptor therapies for treating solid tumors |
US20240075142A1 (en) | 2022-08-26 | 2024-03-07 | Lentigen Technology, Inc. | Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy |
WO2024052503A1 (en) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to ltbp2 and uses thereof |
WO2024064714A2 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Antibodies that bind cd228 |
WO2024092028A2 (en) | 2022-10-25 | 2024-05-02 | Vaccitech North America, Inc. | Combination treatment regimes for treating cancer |
WO2024092030A1 (en) | 2022-10-25 | 2024-05-02 | Vaccitech North America, Inc. | Self-assembling nanoparticles |
US20240165257A1 (en) | 2022-11-01 | 2024-05-23 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
WO2024097816A1 (en) | 2022-11-03 | 2024-05-10 | Seagen Inc. | Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2566271B1 (fr) * | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
US5055561A (en) * | 1985-11-19 | 1991-10-08 | The Johns Hopkins University | Protein label and drug delivery system |
US4981979A (en) * | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
US5002883A (en) * | 1987-10-30 | 1991-03-26 | Abbott Laboratories | Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents |
IL89220A (en) * | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
US5066490A (en) * | 1988-06-01 | 1991-11-19 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Protein crosslinking reagents cleavable within acidified intracellular vesicles |
US5024834A (en) * | 1988-07-12 | 1991-06-18 | Cetus Corporation | Thioether linked immunotoxin conjugates |
CA2016584C (en) * | 1989-05-17 | 1999-06-29 | Robert S. Greenfield | Anthracycline conjugates having a novel linker and methods for their production |
US5208323A (en) * | 1989-08-10 | 1993-05-04 | Universite Laval | Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent |
CA2076347C (en) * | 1990-02-20 | 1996-11-26 | Ravinder K. Gupta | Improved antibody-enzyme direct conjugates and method of making same |
US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
US5196522A (en) * | 1990-11-01 | 1993-03-23 | Board Of Regents, The University Of Texas System | Anthracycline analogues bearing latent alkylating substituents |
-
1992
- 1992-01-23 US US07/824,951 patent/US5622929A/en not_active Expired - Fee Related
- 1992-02-12 TW TW081100979A patent/TW213921B/zh active
-
1993
- 1993-01-14 CA CA002087286A patent/CA2087286C/en not_active Expired - Fee Related
- 1993-01-18 OA OA60332A patent/OA09859A/en unknown
- 1993-01-19 ES ES93100732T patent/ES2240959T3/es not_active Expired - Lifetime
- 1993-01-19 EP EP93100732A patent/EP0554708B9/en not_active Expired - Lifetime
- 1993-01-19 DK DK93100732T patent/DK0554708T3/da active
- 1993-01-19 DE DE69333800T patent/DE69333800T2/de not_active Expired - Lifetime
- 1993-01-19 AT AT93100732T patent/ATE294592T1/de not_active IP Right Cessation
- 1993-01-20 AU AU31881/93A patent/AU666903B2/en not_active Ceased
- 1993-01-21 ZA ZA93444A patent/ZA93444B/xx unknown
- 1993-01-21 EG EG3593A patent/EG20406A/xx active
- 1993-01-21 JP JP5040372A patent/JPH0625012A/ja active Pending
- 1993-01-21 MX MX9300298A patent/MX9300298A/es unknown
- 1993-01-21 FI FI930240A patent/FI930240A/fi unknown
- 1993-01-21 HU HU9300156A patent/HUT68345A/hu unknown
- 1993-01-21 CZ CZ0005793A patent/CZ297409B6/cs not_active IP Right Cessation
- 1993-01-21 NZ NZ245725A patent/NZ245725A/en not_active IP Right Cessation
- 1993-01-21 RO RO93-00069A patent/RO112618B1/ro unknown
- 1993-01-21 IL IL104475A patent/IL104475A0/xx unknown
- 1993-01-21 MY MYPI93000096A patent/MY110526A/en unknown
- 1993-01-21 NO NO93930189A patent/NO930189L/no not_active Application Discontinuation
- 1993-01-22 PL PL93317715A patent/PL172824B1/pl not_active IP Right Cessation
- 1993-01-22 PL PL93317519A patent/PL172715B1/pl not_active IP Right Cessation
- 1993-01-22 BG BG97335A patent/BG61899B1/bg unknown
- 1993-01-22 PL PL93317516A patent/PL172718B1/pl not_active IP Right Cessation
- 1993-01-22 PL PL93297514A patent/PL172828B1/pl not_active IP Right Cessation
- 1993-01-22 PL PL93317518A patent/PL172827B1/pl not_active IP Right Cessation
- 1993-01-22 PL PL93317517A patent/PL172837B1/pl not_active IP Right Cessation
- 1993-01-23 CN CN93100709A patent/CN1040540C/zh not_active Expired - Fee Related
- 1993-01-25 UY UY23541A patent/UY23541A1/es unknown
-
1995
- 1995-06-06 US US08/469,840 patent/US5708146A/en not_active Expired - Fee Related
- 1995-06-06 US US08/468,162 patent/US5606017A/en not_active Expired - Fee Related
-
1997
- 1997-08-26 CN CN97117785A patent/CN1207946A/zh active Pending
- 1997-08-29 CN CNB971179085A patent/CN1155620C/zh not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL172828B1 (pl) | Nowe zwiazki, pochodne hydrazonu PL PL PL PL PL | |
US5728868A (en) | Prodrugs of protein tyrosine kinase inhibitors | |
US6512101B1 (en) | Branched hydrazone linkers | |
EP0294294B1 (en) | Amine derivatives of anthracycline antibiotics | |
JP3010319B2 (ja) | 新規二官性連結化化合物及びその製法 | |
US4950738A (en) | Amine derivatives of anthracycline antibiotics | |
US6214345B1 (en) | Lysosomal enzyme-cleavable antitumor drug conjugates | |
EP0646019B9 (en) | Biotin-DOTA conjugates and their use in pretargeting methods | |
EP0317957A2 (en) | Drug-monoclonal antibody conjugates | |
JPH05501726A (ja) | 生物活性剤用新規リンカー | |
US6150341A (en) | Vitamin B12 derivatives and methods for their preparation | |
WO1990003401A1 (en) | Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages | |
US5770731A (en) | Improvements relating to prodrugs | |
CA2239183C (en) | Branched hydrazone linkers | |
AU2003204343B2 (en) | Vitamin B12 derivatives and methods for their preparation | |
AU4490099A (en) | Vitamin B12 derivatives and methods for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Decisions on the lapse of the protection rights |
Effective date: 20090122 |